Sean J. Hart, PHD
Chief Executive Officer & Chief Scientific Officer
Dr. Hart is a highly accomplished leader, innovator and scientist who has developed transformative, cutting edge technologies throughout his career. In 2012, Dr. Hart founded LumaCyte, a revolutionary biopharmaceutical research, instrumentation, and analytics company. LumaCyte offers biopharmaceutical and biomanufacturing companies an advanced label-free approach to single cell analysis and sorting. Dr. Hart led his team over a 12-year period of development at the Naval Research Laboratory (NRL), managing approximately $15M in initial funding, where the core technologies underlying LumaCyte's products were born. As the original inventors of this novel technology, Dr. Hart and his team have pioneered the scientific advances that have enabled label-free single cell analysis and sorting to be a reality today.
Dr. Hart’s leadership and drive have been cornerstone to LumaCyte’s success and global growth trajectory. His tenacity has been instrumental from corporate inception, accelerating product development and corporate operations, to supporting business development and ongoing R&D. He also serves as LumaCyte’s Chairman of the Board. Dr. Hart expects that LumaCyte's innovative Laser Force Cytology technology will transform personalized medicine, as LumaCyte products may be used to advance customized patient treatments, enabling a more efficient and effective approach in accelerating therapies and find cures.
Dr. Hart has authored 60+ peer reviewed journal articles, numerous invited and contributed presentations, as well as 8 patents issued and 12 pending. Dr. Hart has extensive experience in a diverse range of research areas including spectroscopy, fiber-optics, laser trapping and separation, optical engineering, chromatography, chemical and biochemical separation, multivariate statistical data analysis/calibration, artificial intelligence and machine learning. Dr. Hart received his PhD in Chemistry from Tufts University in 1998. Dr. Hart resides with his wife, Renee, and their three children, Rowan, Sinclaire and Harrison on a farm in Keswick, Virginia.
Renée A. Hart
President & Chief Business Officer
As a member of the Board of Directors and LumaCyte’s President and Chief Business Officer, Renee leads LumaCyte’s corporate development and investor relations, as well as global sales and marketing. She brings over 20 years of executive level business development, operations and strategic partnering experience across the biopharmaceutical, software and clinical development service arenas. Renee’s expertise in managing large scale, highly complex strategic partnerships has garnered her many long-term trusted relationships and oversight across significant multi-million dollar partnerships and transactions in the life science space.
Prior to joining LumaCyte, Renee was SVP and head of the global partner business unit for Medidata Solutions where she led strategic efforts for driving deeper and broader global market penetration of Medidata’s clinical cloud platform for clinical trials. She has also held executive level roles at both Syneos Health (previously inVentiv Health) and Clinipace Worldwide, bringing valuable corporate and executive level leadership and governance experience to her role.
Renee’s experience and earned expertise has touched every aspect of the biopharmaceutical and life sciences industry, providing her a unique perspective into the needs and challenges of the market. Her collaborative spirit and strong focus on solution management coupled with her philosophy of driving growth through innovation and high trust partnership is proving very valuable in accelerating the adoption of LumaCyte’s transformative, game changing technology and global business. Renee has a Bachelor of Science degree in biology from Marshall University.
Colin Hebert, PHD
Vice President, Biotechnology
Dr. Hebert earned a Ph.D. in Bioengineering from the Fischell Department of Bioengineering at the University of Maryland. He was part of the technical team at the Naval Research Laboratory that developed the technology underlying LumaCyte's Radiance instrument. In addition to his contributions to the label-free cell analysis platform, he has also authored 10 peer reviewed journal articles
In his role at LumaCyte, Dr. Hebert oversees technical operations including instrument R&D, LumaCyte’s BSL-2 cell culture facilities, designing internal and external biological experiments and managing the design and construction of our analytical platforms.